Kornimate/medical-research-clean huggingface dataset:
yang yin fu zheng jie du therapy in hbv related hepatocellular carcinoma induced anemia (yyfzjdtihbvrhcia)

Conditions: Hepatocellular Carcinoma

Summary: clinical research of yang yin fu zheng jie du therapy in hbv related hepatocellular carcinoma induced anemia. the purpose of this study is to observe the efficacy of routine medical care combined with yang yin fu zheng jie du therapy for patients belong to hbv-hcc induced anemia.


Eligibility criteria:
inclusion criteria: * meet the criteria of hepatocellular carcinoma * patients who tested positive for hepatitis b surface antigen (hbsag) for \>6 months * meet the criteria of anemia * ages eligible for study: ≤75 years old; * informed consent from the patient. exclusion criteria: * patients with upper gastrointestinal bleeding within 3 months before enrollment; * history of blood transfusion within 3 months before enrollment; * patient with other chronic hepatopathy, such as aih, nafld, ald; * serious problem of heart, lung, or kidney with severe dysfunction; * pregnant or child breast feeding women; * mental or cognitive disorders; * participating in other drug trials; * who are allergic to the study drug.
factorial optimization trial to test effects of coping intervention components

Conditions: Anxiety; Depression; Coping Skills; Emotional Problem

Summary: this study will identify components for inclusion in a coping intervention package to reduce mental health problems among children exposed to high interparental conflict after parental separation/divorce. reappraisal, distraction, and relaxation coping strategies are related to fewer mental health problems among children, making intervention components based on these strategies key candidates for inclusion in an optimized coping intervention. the primary aim is to experimentally assess the main and interactive effects of three digital intervention coping components (reappraisal, distraction, relaxation) on children's coping efficacy, emotional security, and internalizing and externalizing problems. secondary aims are to assess indirect effects of the intervention components on children's coping efficacy, emotional security, and internalizing and externalizing problems through their cognitive, emotional, and behavioral reactions to post-separation/divorce interparental conflict events.

a randomized and counterbalanced 2x2x2 factorial trial (n = 144 children, ages 9-12) will be conducted to assess the individual effects of the three digital coping intervention components. the three components to be tested will be: (1) reappraisal (no vs. yes), (2) distraction (no vs. yes), (3) relaxation (no vs. yes). components that meet a priori thresholds for meaningful change will be combined to form an intervention package that will be evaluated in a subsequent randomized controlled trial.

Eligibility criteria:
inclusion criteria: * child between ages 9-12 whose parents are separated or divorced * child and one parent are fluent in english * a parent with sufficient contact (i.e., at least 4 overnights and/or 12 daytime visits per month) with child who is willing to complete study assessments and has legal right to give permission for the child to participate in research * child-report of high exposure to ipc (mean z score ≥ 40th percentile on the two child report measures of ipc; score standardization based on data from 559 youth whose parents participated in an experimental parenting program) * elevated internalizing or externalizing problems (t score in the borderline clinical range according to either child or parent report on the bpm). exclusion criteria: * in active therapy * score ≥ 99th percentile on either internalizing and externalizing problems subscale * endorse suicidality (will be ineligible for the study and referred for treatment)

Keywords: optimization parental divorce/separation interparental conflict adaptive coping child mental health
patient navigation for colorectal cancer screening for patients with mental illness and/or substance use disorder

Conditions: ColoRectal Cancer Screening

Summary: the investigators propose to develop, implement, and evaluate a novel colorectal (crc) screening patient navigator program for patients with mental health (mh) and /or substance use disorder (sud) receiving care at massachusetts general hospital charlestown. the study will involve randomly assigning eligible patients to early intervention or usual care/delayed intervention groups. the investigators believe this random assignment is ethical because patient navigation (pn) is an extremely limited resource, and all patients identified as eligible could not be contacted by the navigators in a short period of time. thus the investigators will randomly assign access to pn during the study period, and then allow all patients to be navigated and screened after the study period is over. as a result, all eligible patients will be referred for pn, but the timing of the referral will be randomly assigned.


Eligibility criteria:
inclusion criteria: * adult patients aged 50-75 years who are not up to date on crc screening (did not have had crcs colonoscopy in the last 10 years or sigmoidoscopy in the last 5 years or fecal occult blood within last 12 months) * receive care at mgh charlestown * have documented history of mh or sud in electronic medical record exclusion criteria: * subsequently identified as having died prior to study intervention * patients with total colectomy
immunogenicity and safety of imovax polio in chinese infants compared to local opv

Conditions: Poliomyelitis; Polio

Summary: this study is intended to support the registration of imovax polio in china. the primary objective of this pase iii trial is to compare imovax polio to the current chinese standard of care (opv) that is administered following a schedule of 2-3-4 months. the objective is to demonstrate that after the 3 doses primary series, in terms of seroprotection rates, imovax polio is not inferior to opv. the safety of ipv will be assessed after each ipv dose.


Eligibility criteria:
inclusion criteria: * aged 2 months (60-70 days) on the day of inclusion into the study * born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2ibs) or more * parent(s) or legal representative able to understand and give authorization and sign informed consent for participation * able to attend all planned clinic appointment and obey and follow all study instructions exclusion criteria: * taking part in another clinical trial during the 4 weeks before the first trial vaccination * have plans to take part in another clinical trial d during this trial period * inborn or acquired decreased body natural defense, undertaking treatment that can reduce body's natural defense such as cancer drugs, radiation in the past six months or long term corticosteroid treatment * systemic reaction to any vaccine component or history of life-threatening reaction to study vaccine or any vaccine with the same ingredient(s) * prolonged or long time illness that could interfere with study or full participation * received blood or blood-derived products since birth * received any vaccine in the 4 weeks before the first trial vaccination is given (except bcg and hepatitis b) * have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination is given (except dtacp) * previous vaccination against the poliomyelitis infection with the trial vaccine or another vaccine * history of poliomyelitis infection (confirmed either by symptoms, blood or other laboratory test) * clinical or serological evidence of systemic illness including hepatitis b, hepatitis c or human immunodeficiency virus (hiv) * bleeding disorder or a low platelet which do not allow vaccination into the muscle * had seizures in the past * febrile illness (axillary temperature ≥ 37.1°c) or acute illness on the day of inclusion

Keywords: imovax polio poliomyelitis
safety, tolerability, and preliminary efficacy study of als-357 in patients with cutaneous metastatic melanoma

Conditions: Melanoma

Summary: a phase i trial to evaluate the safety and tolerability of als-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied als-357 on histological remission of cutaneous metastatic melanoma and induction of apoptotic biomarkers.


Eligibility criteria:
inclusion criteria: * study participants must be 18 years or older. * study participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery. * study participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.

Keywords: cutaneous metastatic melanoma
efficacy and safety of fermented cinnamon vine powder on decrement of body fat

Conditions: Obesity

Summary: the investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of fermented cinnamon vine powde on decrement of body fat. the investigators measured decrement of body fat parameters , including abdominal fat, body fat mass, ldl-c, hdl-c, total cholesterol and triglyceride, and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: * males and females 19-55 years old * bmi(body mass index) ≥ 25 kg/m\^2 or wc(waist circumference) ≥ 90(men), wc ≥ 85(women) * able to give informed consent exclusion criteria: * significant variation in weight(more 10%) in the past 3 months * allergic or hypersensitive to any of the ingredients in the test products * history of reaction to any of the test products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * history of alcohol or substance abuse * participation in any other clinical trials within past 2 months * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * pregnant or lactating women etc.
the dose effect of extracorporeal shock wave therapy in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the shock wave is a new and potential intervention for the reinnervation of peripheral nerve. the purpose of this study was to assess the dose effect of extracorporeal shock wave therapy on carpal tunnel syndrome.

the investigator perform a prospective randomized, single-blinded study to investigate the dose effect of eswt in patients with carpal tunnel syndrome. the evaluation was performed pretreatment as well as on the 4th, 8th, 12th, 16th and 24 week after the treatment.

Eligibility criteria:
inclusion criteria: 1. age between 20-80 year-old. 2. typical symptoms and signs of cts, such as positive tinel's sign or phalen's test, numbness/tingling in at least two of the first, second, or third digits, and in whom the diagnosis was confirmed using an electrophysiological study. exclusion criteria: 1. cancer 2. coagulopathy 3. pregnancy 4. inflammation status 5. patients who had conditions mimicking cts, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously undergone wrist surgery or steroid injection for cts.
study of compound danshen dripping pills to treat acute mountain sickness

Conditions: Acute Mountain Sickness

Summary: this study is to evaluate the efficacy and safety of compound danshen dripping pills in preventing and treating acute mountain sickness.

compound danshen dripping pills is mainly used for the treatment and prevention of coronary heart disease and high-risk groups ,consists of danshen (radix salviae miltiorrhizae), sanqi (radix notoginseng) and borneol.danshen is the main drug efficacy of stasis, nourishing the nerves.pharmacological studies have shown that danshen can improve the oxygen carrying capacity of blood, increase oxygen supply to vital organs, effectively reduce hypoxia-induced heart and other vital organs, brain and kidney damage. danshen can activate the fibrinolytic system, reduce blood viscosity, clear the microcirculation, promote blood circulation, increasing the amount of tissue oxygen by inhibiting platelet aggregation.this study is being conducted to evaluate the efficacy and safety of compound danshen dripping pills in preventing and treating acute mountain sickness, when compared with placebo.

Eligibility criteria:
inclusion criteria: * aged 18-45 years，male or female, plain natives * first stationed at high altitude above 3,000 meters * upon physical examination before enrollment in good health * bmi 19 to 24; (weight kg / height sqm ) * voluntary signs the informed consent exclusion criteria: * menstruation, pregnancy and breast-feeding women * smoking, alcohol and drug abusers * clear history of drug allergy or allergic persons * application of various drugs (including traditional chinese medicine) two weeks ago * combined with severe liver and kidney dysfunction (cardiac function grade ≥3, liver function grade \> 2 times of the upper limit of normal, cr\> upper limit of normal); * subject with blood donation experiences or blood test experiences within three months before be selected. * c- reactive protein test results exceed the upper limit of normal. * clinically significant gastrointestinal disease, mental illness and diabetes, hyperthyroidism and other metabolic diseases; * past suffering from cardiovascular and cerebrovascular disease * fatigue syndrome that is not by high altitude-induced * primary headache * vomiting due to other causes, such as digestive disorders as a result of the vomiting reflex, vomiting vestibular disorders, neurotic vomiting; * allergies * who participated in clinical trials of other drugs within a month * blood circulation, increase immunity and antioxidant drug users

Keywords: acute mountain sickness compound danshen dripping pills
the resting-state eeg gamma oscillations in alzheimer's disease

Conditions: Alzheimer Disease, Early Onset

Summary: the literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for alzheimer's pathology. the present study aims to investigate resting-state gamma activity changes in cerebrospinal fluid (csf)-proven early-onset alzheimer's disease (eoad) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

this cross-sectional study included 24 drug-naive csf-proven eoad patients and age-, sex, and education-matched healthy controls. all participants underwent a detailed neuropsychological evaluation, resting-state electroencephalography (eeg) recording, and magnetic resonance imaging (mri). gamma power and coherence were measured in total gamma (30-48 hz), gamma-1 (30-35 hz), gamma-2 (35-40 hz), and gamma-3 (40-48 hz) frequency bands. gray matter volumes were extracted for 54 regions of interest (rois) and compared between groups. discriminant analysis was performed to determine the classification accuracy of gamma activity for eoad. finally, correlations between csf, neuropsychological tests, eeg, and mri measures were explored.

Eligibility criteria:
inclusion criteria: * for all participants: age \< 65 * for eoad patients: meeting national institute on aging-alzheimer's association diagnostic criteria. * for healthy controls: mini-mental state examination (mmse) \>25 instrumental activities of daily living scale (iadl) = 8 exclusion criteria: * for eoad patients: mmse \> 24 geriatric depression scale (gds) \> 14 having treatment with antipsychotics and comorbidities that may affect cognitive abilities. * for healthy controls: having neurological and/or cognitive abnormalities having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. gds \> 14 * for all participants: having neurological (other than ad) or any other serious disease (cancer, systemic disease)

Keywords: alzheimer's disease gamma activity resting-state eeg discriminative power mri
hyaluronic acid and vaginal distress

Conditions: Vaginal Disease

Summary: the purpose of this trial is to study the effects of the oral supplementation hyaluronic acid in menopause women with vaginal distress for treatment vaginal distress.


Eligibility criteria:
inclusion criteria: * menopause * vaginal distress * no other therapy exclusion criteria: * vaginal infection * sjogren syndrome
evaluation of the efficacy and safety of a fixed-dose, single-capsule budesonide-formoterol combination in uncontrolled asthma

Conditions: Asthma

Summary: to evaluate the efficacy and safety of a fixed-dose, single-capsule budesonide(400µg)-formoterol(12µg) combination, in comparison with budesonide alone, both delivered via a dry powder inhaler, in 181 patients with uncontrolled asthma.this was randomized, double-blind, multicenter, phase iii, parallel clinical trial.

the age of the patients ranged from 18 to 77 years. after a run-in period of 4 weeks, during which all of the patients received budesonide twice a day, they were randomized into one of the treatment groups for 12 weeks, twice a day. the primary outcome measures were fev1, fvc and morning pef. we performed an intention-to-treat analysis of the data.

Eligibility criteria:
inclusion criteria: * diagnosis of uncontrolled asthma * age ranged from 18 to 77 years * nonsmokers exclusion criteria: * use of oral corticosteroids, anti-leukotrienes, immunoglobulins, beta blockers, digitalis, amiodarone, antifungals, antidepressants, monoamine oxidase inhibitors and tricyclics during the standardization * atrial fibrillation, flutter, severe and complex tachyarrhythmias atrioventricular block 1,2 and 3 * diabetes mellitus * pregnancy * neuropsychiatric diseases * pulmonary malformations, tuberculosis, cystic fibrosis * immunosuppressive treatment * hospitalization for asthma or respiratory infection in last 30 days * severe systemic disease

Keywords: asthma budesonide adrenergic beta-2 receptor agonists.
safety and outcome of contemporary treatment strategies for cardiogenic shock

Conditions: Cardiogenic Shock

Summary: international, observational registry to investigate the outcome in patients with cardiogenic shock. the primary aim of this study is to investigate the clinical outcome of patients in cardiogenic shock.

there is a focus on interventional therapies, mechanical circulatory support and new cardiovascular therapeutics in patients with cardiogenic shock (cs). the investigators will describe current practice in study sites including concomitant patients with cs. therefore, the investigators will monitor drug therapies initiated, devices being utilized as well as outcome and side effect of possible interventions

Eligibility criteria:
inclusion criteria: * patients with cardiogenic shock treated at a tertiary care hospital. exclusion criteria: * age ≤17 years.
comparison of rca and racd in extra-renal purification by sled

Conditions: Acute Kidney Injury

Summary: one of the main rrt issues is anticoagulation of the ecc, because blood contact with biomaterials causes bio-incompatibility reactions, including activation of the coagulation cascade. based on regional citrate anticoagulation (rca) protocols, an ionized calcium (ca-ion) concentration around 0.25 to 0.35mmol / l prevents fibrino formation and allows anticoagulation for the ecc. during rca, metabolic side effects may occur due to systemic flow of citrate. our postulate is that reduction of ionized calcemia related to the use of a calcium-free dialysate and haemofilter performance makes it possible to avoid citrate infusion. our study aim to compare intermittent rrt using 4% citrate infusion and without citrate.

background: renal replacement therapy (rrt), requires anticoagulation of the extracorporal circuit (ecc) using heparin, citrate or repeated rinsing. difficulties of implementation or exposition to complications (thrombosis, hemorrhage or electrolyte disorder) are frequent. purpose: regional anticoagulation of the ecc based on ionized calcemia reduction, as using citrate, but induced by the use of a calcium-free dialysate associated with the performance of the hemofilter could reduce these risks and the cost of intermittent rrt. this study aims to compare the efficiency of a regional anticoagulation technique based on the reduction of ionized calcium in the extracorporal circuit, without the use of citrate and with citrate during intermittent rrt. abstract: one of the main rrt issue is anticoagulation of the ecc, because blood contact with biomaterials causes bio-incompatibility reactions, including activation of the coagulation cascade. based on regional citrate anticoagulation (rca) protocols, an ionized calcium (ca-ion) concentration around 0.25 to 0.35mmol/l prevents fibrino formation and allows anticoagulation for the ecc. during rca, metabolic side effects may occur due to systemic passage of citrate. our postulate is that reduction of ionized calcemia related to the use of a calcium-free dialysate and haemofilter performance makes it possible to avoid citrate infusion. our study aims at comparing intermittent rrt using 4% citrate infusion and without citrate.

Eligibility criteria:
inclusion criteria: * all patient requiring renal replacement therapy exclusion criteria: * age \< 18 years * pregnancy * hypercalcemia ≥ 3 mmol/l. * major under guardianship * major deprived of freedom * impossible to obtain free and informed consent * presence of hemostasis or coagulation disorders: * thrombocytopenia \< 30 g/l. * curative anticoagulation. * severe liver disease with prothrombin rate \<30%. * coagulation factor deficit. * not registered to a social security system.
effects of a new dispatcher-assisted basic life support training program

Conditions: Out of Hospital Cardiac Arrest

Summary: despite aggressive cardiopulmonary resuscitation (cpr) training, the outcome of cardiac arrest is not good. the problem is method of education. so, the investigators want to add the dispatcher-assisted cpr simulation into conventional cpr training. in this study, the study is aimed to investigate the effect of newer cpr training program.

the training program focuses on working in team with dispatcher, performing all steps from recognizing cardiac arrest to performing cpr, together with the dispatcher. the one hours training session is split into four parts: 1. video self-instruction manikin practice (30 min), including a brief introduction to automated external defibrillator (aed). 2. practice in pairs (15 min). practicing the dispatcher and rescuer role in a simulation to enhance learning. 3. debriefing. questions, answers and reflection (15 min). 4. homework. leaflet with tasks like learn how to activate the speaker function on your own phone. the main difference between dispatcher-assisted basic life support (da-bls) and traditional bls training is that da-bls provides the scenes and interactive experiences on calling emergency medical service (ems) and receiving cpr instruction via telephone speaker function, following up the skill training by scenario simulation training.

Eligibility criteria:
inclusion criteria: * all out-of-hospital cardiac arrest (ohca) patients with presumed cardiac etiology who are 19 years of age or older and assessed and treated by ems providers after dispatched by the ems dispatch center will be included. exclusion criteria: * we will exclude patients with non-cardiac etiology, prolonged cardiac arrest with a suspected duration more than 30 minutes, cases such as livor mortis or rigor mortis, and decapitated or decomposed body, and patients who have "do-not-resuscitate" card documented by doctor.

Keywords: cardiac arrest dispatcher-assisted bystander cardiopulmonary resuscitation survival